The aim of this retrospective observational cohort study was to evaluate the impact of DMARDs, CS and the three TNFα antagonists licensed in Italy between 2001 and 2005, in mono or combination therapy, on non-serious and serious infections in RA and SpA patients. Here, TNF is linked to rheumatoid arthritis.